MANKINDMankind Pharma Ltd.

    Mankind Pharma Ltd: results and news

    Every Mankind Pharma Ltd filing with the NSE and BSE that Blacklitt has written about, explained in plain words and linked to the filing, newest first: mergers & acquisitions, credit rating, earnings.

    4 articles · Pharmaceuticals · Latest 30 Oct 2026

    A pile of assorted tablets and capsules

    MANKINDMankind Pharma Ltd

    Mankind Pharma to acquire a 70% stake in CAR-T developer Armed Cell Therapeutics for about €48 million

    Mankind Pharma Limited has told the exchanges that its board, at a meeting on 15 Oct 2026, approved an additional investment of up to €45 million in its wholly owned Netherlands subsidiary, Mankind Pharma (Netherlands) B.V., in one or more tranches. That raises the aggregate investment limit to €50 million, including the €5 million approved earlier.

    • Mergers & acquisitions
    • Pharmaceuticals

    Blacklitt Research2 min read